Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track ELVN with free AI briefings, catalyst countdowns, and dilution alerts.

ELVN · Enliven Therapeutics, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$884.4M Cash on Hand
170.7mo Cash Runway
Follow ELVN by email Get an email when ELVN reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about ELVN, unsubscribe in one click. Privacy

📣 What ELVN Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Relcobatinib (ELVN-001) Chronic Myeloid Leukemia (CML) Phase 3 · NCT07905183 Not yet recruiting
Fluorouracil HER2-positive Breast Cancer Phase 1 · NCT06328738 Active not recruiting
HER2 Inhibitor ELVN-002 HER2 Mutant Non-small Cell Lung Cancer Phase 1 · NCT05650879 Active not recruiting
Eribulin HER2-positive Breast Cancer Phase 1 · NCT06328738 Active not recruiting
Trastuzumab Emtansine HER2 Mutant Non-small Cell Lung Cancer Phase 1 · NCT05650879 Active not recruiting

Also used in these trials (approved or third-party drugs, not ELVN's own candidates): Dasatinib, Capecitabine, Fam-Trastuzumab Deruxtecan-Nxki, Leucovorin, Oxaliplatin, Paclitaxel, Trastuzumab.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

ELVN holds $884.4M in cash and short-term investments (as of Sep 30, 2026) and burns about $15.5M/quarter from operations, an estimated runway of 170.7 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 17 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ELVN files for a raise →

👥 Who Owns ELVN

Insiders 10.6% Institutions (318 holders) 89.4% Public and other holders 0%
HolderTypeShares% of sharesAs of
FMR LLC Institution (13G, 5%+) 10,713,540 14.56% 2026-06-30
ORBIMED ADVISORS LLC
10% owner
Insider 6,555,102 8.91% 2026-06-22
BlackRock, Inc. Institution (13G, 5%+) 5,206,581 7.07% 2026-09-30
Polar Capital Holdings Plc Institution (13G, 5%+) 5,056,807 6.87% 2026-03-31
Commodore Capital LP Institution (13G, 5%+) 4,800,940 6.52% 2026-03-31
Joseph P Lyssikatos
CHIEF SCIENTIFIC OFFICER · +112,500 options
Insider 758,938 1.03% 2026-02-12
Anish Patel
CHIEF OPERATING OFFICER · +120,000 options
Insider 235,011 0.32% 2026-02-12
Richard A. Heyman
Director · +19,234 options
Insider 149,218 0.20% 2026-02-17
Lori Anne Kunkel
Director · +47,708 options
Insider 52,925 0.07% 2026-10-30
Benjamin Hohl
CHIEF FINANCIAL OFFICER · +409,966 options
Insider 38,000 0.05% 2026-10-19
Helen Louise Collins
CHIEF MEDICAL OFFICER · +251,268 options
Insider 25,000 0.03% 2026-10-19

Share count 73,595,132 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full ELVN picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ELVN and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.